Literature DB >> 31079322

Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.

Armin Sepp1, Guy Meno-Tetang2,3, Andrew Weber4, Andrew Sanderson5, Oliver Schon5,6, Alienor Berges2,7.   

Abstract

Two-pore physiologically-based pharmacokinetic (PBPK) models can be expected to describe the tissue distribution and elimination kinetics of soluble proteins, endogenous or dosed, as function of their size. In this work, we amalgamated our previous two-pore PBPK model for an inert domain antibody (dAb) in mice with the cross-species platform PBPK model for monoclonal antibodies described in literature into a unified two-pore platform that describes protein modalities of different sizes and includes neonatal Fc receptor (FcRn) mediated recycling. This unified PBPK model was parametrized for organ-specific lymph flow rates and the endosomal recycling rate constant using an extended tissue distribution time-course dataset that included an inert dAb, albumin and IgG in rats and mice. The model was evaluated by comparing the ab initio predictions for the tissue distribution and elimination properties of albumin-binding dAbs (AlbudAbsTM) in mice and rats with the experimental observations. Due to the large number of molecular species and reactions involved in large-scale PBPK models, we have also developed and deployed a MatlabTM script for automating the assembly of SimBiologyTM-based two-pore biologics PBPK models which drastically cuts the time and effort required for model building.

Entities:  

Keywords:  AlbudAbTM; Albumin; Antibody; Domain antibody; Physiologically based pharmacokinetics

Mesh:

Substances:

Year:  2019        PMID: 31079322     DOI: 10.1007/s10928-019-09640-9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  69 in total

1.  BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.

Authors:  John F Graf; Bernhard J Scholz; Maria I Zavodszky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-10       Impact factor: 2.745

2.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

3.  Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces.

Authors:  Jonghan Kim; C L Bronson; William L Hayton; Michael D Radmacher; Derry C Roopenian; John M Robinson; Clark L Anderson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-10-06       Impact factor: 4.052

Review 4.  Mathematical modeling as accounting: predicting the fate of serum proteins and therapeutic monoclonal antibodies.

Authors:  Brian Gurbaxani
Journal:  Clin Immunol       Date:  2006-11-22       Impact factor: 3.969

Review 5.  Perspective-- FcRn transports albumin: relevance to immunology and medicine.

Authors:  Clark L Anderson; Chaity Chaudhury; Jonghan Kim; C L Bronson; Manzoor A Wani; Sudhasri Mohanty
Journal:  Trends Immunol       Date:  2006-05-30       Impact factor: 16.687

6.  Quantification of IgG monoclonal antibody clearance in tissues.

Authors:  Miro J Eigenmann; Ludivine Fronton; Hans Peter Grimm; Michael B Otteneder; Ben-Fillippo Krippendorff
Journal:  MAbs       Date:  2017-06-14       Impact factor: 5.857

Review 7.  Endosome maturation, transport and functions.

Authors:  Cameron C Scott; Fabrizio Vacca; Jean Gruenberg
Journal:  Semin Cell Dev Biol       Date:  2014-04-04       Impact factor: 7.727

8.  Renal clearance of human and rat albumins in the rat.

Authors:  M Gaizutis; A J Pesce; V E Pollak
Journal:  Proc Soc Exp Biol Med       Date:  1975-04

9.  Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs.

Authors:  Lucy J Holt; Amrik Basran; Kate Jones; Jennifer Chorlton; Laurent S Jespers; Neil D Brewis; Ian M Tomlinson
Journal:  Protein Eng Des Sel       Date:  2008-04-02       Impact factor: 1.650

10.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

View more
  4 in total

1.  Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans.

Authors:  Armin Sepp; Mats Bergström; Marie Davies
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

2.  Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans.

Authors:  Prabhas Jagdale; Armin Sepp; Dhaval K Shah
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-10-20       Impact factor: 2.410

3.  Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies.

Authors:  Morris Muliaditan; Armin Sepp
Journal:  Clin Transl Sci       Date:  2022-04-28       Impact factor: 4.438

4.  Diagnostic biomarker kinetics: how brain-derived biomarkers distribute through the human body, and how this affects their diagnostic significance: the case of S100B.

Authors:  Robert Murcko; Nicola Marchi; Damian Bailey; Damir Janigro
Journal:  Fluids Barriers CNS       Date:  2022-05-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.